Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma

Meng Li¹,², *, Sirui Fu³, *, Yanjie Zhu⁴, Zaiyi Liu², Shuting Chen², Ligong Lu³ and Changhong Liang²

¹ Southern Medical University, Guangzhou, China
² Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
³ Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
⁴ Shenzhen Institutes of Advanced Technology, Shenzhen, China

* These authors have contributed equally to this manuscript

Correspondence to: Ligong Lu, email: llg0902@sina.com
Correspondence to: Changhong Liang, email: cjr.lchh@vip.163.com

Keywords: hepatocellular carcinoma, texture analysis, computed tomography, liver resection, transcatheter arterial chemoembolization

Received: November 09, 2015    Accepted: January 27, 2016    Published: February 17, 2016

ABSTRACT

This study explored the potential of computed tomography (CT) textural feature analysis for the stratification of single large hepatocellular carcinomas (HCCs) > 5 cm, and the subsequent determination of patient suitability for liver resection (LR) or transcatheter arterial chemoembolization (TACE). Wavelet decomposition was performed on portal-phase CT images with three bandwidth responses (filter 0, 1.0, and 1.5). Nine textural features of each filter were extracted from regions of interest. Wavelet-2-H (filter 1.0) in LR and wavelet-2-V (filter 0 and 1.0) in TACE were related to survival. Subsequently, LR and TACE patients were divided based on the wavelet-2-H and wavelet-2-V median at filter 1.0 into two subgroups (+ or -). LR+ patients showed the best survival, followed by LR-, TACE+, and TACE-. We estimated that LR+ patients treated using TACE would exhibit a survival similar to TACE- patients and worse than TACE+ patients, with a severe compromise in overall survival. LR was recommended for TACE- patients, whereas TACE was preferred for LR- and TACE+ patients. Independent of tumor size, CT textural features showed positive and negative correlations with survival after LR and TACE, respectively. Although further validation is needed, texture analysis demonstrated the feasibility of using HCC patient stratification for determining the suitability of LR vs. TACE.

INTRODUCTION

Identification and quantification of tumor heterogeneity by computed tomography (CT) textural analysis shows promise in enhancing prognostic accuracy and facilitating therapeutic decision making. Such advances are particularly important for diseases such as liver cancer, which is the second and sixth most frequent cause of cancer related-death in men and women, respectively, with hepatocellular carcinoma (HCC) most common [1]. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, the diameter of a single HCC may not be a contraindication for liver resection (LR) [2-5]. However, most Asian patients with HCC have diseased liver parenchyma, such as hepatitis B virus infection and/or hepatitis B virus-related cirrhosis, and LR in this population is therefore associated with a high risk of complications [6]. This consideration may alter therapy-based decision-making in cases of single HCCs > 5 cm, particularly for potential LR candidates [7, 8]. Asymptomatic patients with a solitary HCC without vascular invasion or extrahepatic spread and with well-preserved liver function could also be considered for transcatheter arterial chemoembolization (TACE) [3, 5, 9].
Thus, to assess whether a patient scheduled to undergo LR would be better suited for TACE and vice versa, reliable prognostic markers for patient stratification are needed.

Proposals for a subclassification system for BCLC stage B tumors have emerged in recent years. One study proposed a stratification system aimed toward tailoring therapeutic interventions based on both the evidence available to date and expert opinions [10]. Another study suggested taking the Child-Pugh score and liver transplantation status into account [11]. In clinical practice, the decision to treat with LR or TACE is made using a combination of clinical symptoms, laboratory test results, and pathological biomarkers, whereas the CT images routinely acquired during treatment and follow-up are largely overlooked. Conventional assessment of tumor size and enhancement of cross-sectional images are far from satisfactory in the determination of an appropriate therapeutic strategy, due to insufficient imaging of the inherent properties of the tumor and interobserver variability in image interpretation.

Radiomics is an emerging research field that aims to utilize the full potential of medical imaging [12]. This includes texture analysis, which is assumed to reflect tissue heterogeneity [13-17]. Heterogeneity is a well-recognized feature reflecting alterations in tissue patterns, likely occurring due to cell infiltration, abnormal angiogenesis, microvasculature and necrosis [18-20]. One study suggested an association between image traits, including textural features, and underlying gene expressions in HCC [21]. Another stated that the radiomic signature could be transferred from lung to head-and-neck cancer, suggesting that this signature identifies a general prognostic tumor phenotype [12]. In fact, texture analysis has shown feasibility in the differential diagnosis of liver cancers [22], hepatic fibrosis detection/staging [23, 24], and prediction of postoperative hepatic insufficiency [25].

In this study, we explored texture analysis as a prognostic and patient stratification approach in the determination of an appropriate therapeutic option, LR or TACE, for patients with single large HCCs. Herein, two questions were raised: (1) are the textural parameters of the primary tumor, calculated from baseline CT, related to prognosis? (2) Does texture analysis have the potential to provide an additional view for treatment modification between LR and TACE?

RESULTS

Patients

A total of 130 patients (86 and 44 treated by LR and TACE, respectively) were retrospectively included for texture analysis. Of these, 106 (81.5%) patients had disease progression, and 96 (73.8%) patients died by the study end date. There were no significant differences in the patient baseline demographics and characteristics (Table 1). All texture features, calculated from two sets of regions of interest (ROIs), showed excellent agreement (ICC value, 0.799-0.999).

Cox regression and Kaplan-Meier analysis for LR and TACE

For candidate clinical and imaging variables, univariate analysis showed that corona ($P = 0.057$) was the only variable with a $P$ value < 0.10 in LR, whereas in TACE, none of the variables showed significant differences (Table 2). For textural features, nine and 21 features in the LR and TACE groups, respectively, were identified as statistically significant (Table S1).

Multivariate Cox models showed that only wavelet-2-H (filter 1.0) in LR and wavelet-2-V (filter 0 and 1.0) and wavelet-3-D (filter 1.5) in TACE were significantly correlated with overall survival (OS) (Table 3).

Separated by the above-identified four textural subgroups (LR- vs. LR+, TACE+, and TACE-), patients were divided into four subgroups: LR-, LR+, TACE+, and TACE-. The LR group had longer TTP (some patients were without recurrence), this group received fewer sessions of subsequent TACE and ablation than patients in the TACE group. As a result, 44 of 86 (51.2%) LR patients (median number of sessions, 0; range, 0-4) and 44 of 44 (100%) TACE patients (median number of sessions, 3; range 1-15) received subsequent TACE, while 9 of 86 (10.5%) LR patients (median number of sessions, 0; range, 0-4) and 16 of 44 (36.4%) TACE patients (median number of sessions, 0; range, 0-3) received subsequent ablation. There were no other differences in patient demographics and characteristics among the four subgroups.

Without detailed subgrouping, patients in the LR group showed better OS ($\chi^2 = 9.809, P = 0.002$) and TTP ($\chi^2 = 5.840, P = 0.016$) than those in the TACE group (Figure 2A & 2D). Subsequently, patients were divided into four subgroups: LR-, LR+, TACE+, and TACE-. Since the LR group had longer TTP (some patients were without recurrence), this group received fewer sessions of subsequent TACE and ablation than patients in the TACE group. As a result, 44 of 86 (51.2%) LR patients (median number of sessions, 1; range, 0-9) and 44 of 44 (100%) TACE patients (median number of sessions, 3; range 1-15) received subsequent TACE, while 9 of 86 (10.5%) LR patients (median number of sessions, 0; range, 0-4) and 16 of 44 (36.4%) TACE patients (median number of sessions, 0; range, 0-3) received subsequent ablation. There were no other differences in patient demographics and characteristics among the four subgroups.

OS showed a significant difference among the four subgroups ($\chi^2 = 24.292, P < 0.001$). Further pairwise comparisons showed that LR- vs. TACE- ($\chi^2 = 8.229, P = 0.004$), LR+ vs. TACE+ ($\chi^2 = 4.425, P = 0.035$) and LR+ vs. TACE- ($\chi^2 = 21.880, P < 0.001$) had significant differences in OS, whereas LR- vs. TACE+ ($\chi^2 = 0.010, P = 0.920$) did not (Figure 2C). Similar results were noted when LR was separated by wavelet-2-H (filter 1.0) and TACE was separated by wavelet-2-V (filter 0) (Figure 2B).
| Table 1: Patient baseline demographics and characteristics | All (n=130) | LR (n=86) | TACE (n=44) | P |
|----------------------------------------------------------|------------|-----------|-------------|---|
| Age (years)                                              | 57 (20–84)*| 56 (30–84)*| 59 (20–81)*| 0.125 |
| Sex (n)                                                  |            |           |             | 0.425 |
| Male                                                     | 114        | 74        | 40          |     |
| Female                                                   | 16         | 12        | 4           |     |
| Body mass index (kg/m²)                                  | 23 (15–32)*| 23 (17–31)*| 24 (15–32)*| 0.304 |
| Hepatitis infection (n)                                  |            |           |             | 0.203 |
| HBV                                                      | 88         | 55        | 33          |     |
| Negative                                                 | 42         | 31        | 11          |     |
| Child–Pugh class (n)                                     |            |           |             | 0.209 |
| A                                                        | 125        | 84        | 41          |     |
| B                                                        | 5          | 2         | 3           |     |
| Performance status                                       |            |           |             | 0.105 |
| 0                                                        | 118        | 81        | 37          |     |
| 1                                                        | 12         | 5         | 7           |     |
| BCLC stage                                               |            |           |             | 0.742 |
| AB (without VI)                                          | 114        | 76        | 38          |     |
| C (with VI)                                              | 16         | 10        | 6           |     |
| Cirrhosis                                                |            |           |             | 0.244 |
| Yes                                                      | 92         | 58        | 34          |     |
| No                                                       | 38         | 28        | 10          |     |
| Maximum diameter (mm)                                    | 80 (51–187)*| 85 (51–150)*| 76 (52–187)*| 0.821 |
| Albumin (g/L)                                            | 36 (23–48)*| 36 (27–48)*| 36 (23–43)*| 0.273 |
| Total bilirubin (μmol/L)                                 | 18 (6–47)*| 17 (6–32)*| 19 (10–47)*| 0.454 |
| Prothrombin time (sec)                                   | 14 (12–16)*| 14 (12–15)*| 14 (12–16)*| 0.418 |
| ALT (U/L, n)                                             | 38(10–566)*| 38(10–236)*| 38(17–566)*| 0.509 |
| AFP level (ng/ml)                                        |            |           |             | 0.369 |
| <25                                                      | 47         | 32        | 15          |     |
| 25–400                                                   | 45         | 32        | 13          |     |
| >400                                                     | 38         | 22        | 16          |     |
| Differentiation(n)                                       |            |           |             |     |
| Unknown                                                  | 44         | 0         | 44          |     |
| Moderate                                                 | 32         | 32        | -           |     |
| Moderate-poor                                            | 11         | 11        | -           |     |
| Poor                                                     | 43         | 43        | -           |     |
| Microvascular invasion(n)                                |            |           |             |     |
| Unknown                                                  | 44         | 0         | 44          |     |
| Negative                                                 | 40         | 40        | -           |     |
| Positive                                                 | 46         | 46        | -           |     |

* Median (range) for data without normal distribution.
LR: liver resection; TACE: transcatheter arterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer; VI: vascular invasion; ALT: alanine aminotransferase; AFP: Alpha fetoprotein;
| Factors                        | LR          |          |          | TACE       |          |
|-------------------------------|-------------|----------|----------|------------|----------|
|                               | n           | HR (95% CI) | P     | n           | HR (95% CI) | P     |
| Sex                           | female      | 12       | reference | 0.843      | 4         | reference | 0.269 |
|                               | male        | 74       | 1.103 (0.419–2.904) | 0.117 (0.071–13345.010) | 40         | 30.802 (0.071–13345.010) |
| Age                           | 86          | 0.981 (0.952–1.012) | 0.225 | 44          | 1.016 (0.987–1.045) | 0.281 |
| BCLC stage*                   | C           | 10       | Reference | 0.117      | 6         | Reference | 0.163 |
|                               | AB          | 76       | 0.427 (0.147–1.237) | 0.380 (0.097–1.478) | 38         | 0.380 (0.097–1.478) |
| Maximum diameter              | 86          | 1.005 (0.994–1.016) | 0.337 | 44          | 0.998 (0.987–1.008) | 0.660 |
| Cirrhosis                     | positive    | 28       | Reference | 0.388      | 10        | Reference | 0.425 |
|                               | negative    | 58       | 0.704 (0.318–1.561) | 0.753 (0.328–1.624) | 34         | 0.753 (0.328–1.624) |
| Child-Pugh Class              | B           | 2        | Reference | 0.940      | 3         | Reference | 0.590 |
|                               | A           | 84       | 1.080 (0.146–7.996) | 41         | 1.518 (0.333–6.921) |
| Hepatitis                     | HBV         | 31       | 0.557 (0.146–2.669) | 0.570 (0.188–1.729) | 11         | 0.570 (0.188–1.729) |
|                               | negative    | 55       | 1.256 (0.587–2.689) | 0.802      | 33         | 0.802 |
| AFP (ng/ml)                   | >400        | 22       | Reference | 0.522      | 16        | Reference | 0.522 |
|                               | <25         | 32       | 1.018 (0.394–2.633) | 0.906 (0.313–2.624) | 15         | 0.906 (0.313–2.624) |
|                               | 25–400      | 32       | 1.593 (0.603–4.209) | 13         | 1.349 (0.412–4.420) |
| Post-TACE                     | yes         | 44       | Reference | 0.791      | -         | All received post-TACE |
|                               | no          | 42       | 0.904 (0.429–1.906) | 0.709      | 42         | 0.904 (0.429–1.906) |
| Post-ablation                 | yes         | 8        | Reference | 0.164      | 16        | Reference | 0.164 |
|                               | no          | 78       | 4.139 (0.560–30.580) | 1.187 (0.482–2.924) | 28         | 1.187 (0.482–2.924) |
| Capsule                       | integral    | 14       | Reference | 0.396      | 14        | Reference | 0.396 |
|                               | absence     | 9        | 1.129 (0.206–6.181) | 3.475 (1.049–11.510) | 14         | 3.475 (1.049–11.510) |
|                               | not integral| 63       | 1.955 (0.667–5.727) | 1.917 (0.619–5.933) | 16         | 1.917 (0.619–5.933) |
| Shape                         | invasive    | 29       | Reference | 0.814      | 23        | Reference | 0.814 |
|                               | non-invasive| 57       | 0.911 (0.419–1.982) | 0.469 (0.186–1.182) | 21         | 0.469 (0.186–1.182) |
| Corona†                       | positive    | 40       | Reference | 0.057      | 15        | Reference | 0.057 |
|                               | negative    | 46       | 0.478 (0.224–1.021) | 0.650 (0.255–1.657) | 29         | 0.650 (0.255–1.657) |
| Mosaic                        | positive    | 67       | Reference | 0.144      | 31        | Reference | 0.144 |
|                               | negative    | 19       | 0.485 (0.184–1.280) | 2.032 (0.773–5.336) | 13         | 2.032 (0.773–5.336) |
| Node in Node                  | All negative|         | All negative | All negative | All negative | All negative |
| Enhance region                | >75%        | 67       | Reference | 0.894      | 38        | Reference | 0.223 |
|                               | 0%-25%      | -        | -        | -          | -        | -        | -        |
|                               | 25%-50%     | 5        | 0.704 (0.095–5.235) | 2.478 (0.300–20.433) | 2         | 2.478 (0.300–20.433) |
|                               | 50%-75%     | 14       | 1.158 (0.438–3.065) | 3.720 (0.768–18.020) | 4         | 3.720 (0.768–18.020) |
TTP also showed a significant difference between the four subgroups ($\chi^2 = 10.969$, $P = 0.012$). Further pairwise comparisons showed that LR - vs TACE- ($\chi^2 = 4.317$, $P = 0.038$) and LR+ vs. TACE- ($\chi^2 = 11.762$, $P = 0.001$) had significant differences in the TTP, whereas LR- vs. TACE+ ($\chi^2 = 0.034$, $P = 0.854$) and LR+ vs. TACE+ ($\chi^2 = 2.299$, $P = 0.129$) did not (Figure 2F). Similar results were noted when LR was separated by wavelet-2-H (filter 0) and TACE was separated by wavelet-2-V (filter 0) (Figure 2E).

In all patients, for OS, univariate Cox regression showed that BCLC, corona, and subgrouping had $P$-values $< 0.10$, and the multivariate Cox regression models confirmed that subgrouping was the only factor that was significantly associated with OS ($P = 0.012$). For TTP, univariate Cox regression showed that the presence of a capsule, corona and subgrouping had $P$-values $< 0.10$, and the multivariate Cox regression models confirmed that the capsule was the only factor that was significantly associated with the TTP ($P = 0.021$).

These results indicate that LR+ was associated with the best survival, followed by LR- and TACE+ ($P = 0.920$ and 0.854 for OS and TTP, respectively, in LR- vs. TACE+), whereas TACE- was associated with the worst survival. Thus, the feasibility of texture features in patient stratification and determination of the most suitable therapy (LR or TACE) was partly confirmed; however, further validation was still considered necessary.

**Further validation**

Since wavelet-2-V (filter 1.0) and wavelet-2-H (filter 1.0) were not normally distributed among the subgroups, Kruskal-Wallis $H$ was used for further analysis.

First, wavelet-2-V (filter 1.0) was compared between LR+ and TACE+, as well as between LR+ and TACE-. The results showed that the value of LR+ was

| Differentiation | Count | Reference | $P$-value | TTP group |
|-----------------|-------|-----------|-----------|-----------|
| poor            | 43    | Reference | 0.713     | Not available in TACE group |
| moderate        | 32    | 1.028 (0.541–1.863) |            |           |
| moderate-poor   | 11    | 0.725 (0.355–1.748)  |            |           |
| MI positive     | 46    | Reference | 0.452     | Not available in TACE group |
| negative        | 40    | 0.703 (0.297–1.742)  |            |           |

Dash indicated no data identified; *in this study, presence of vascular invasion was represented by BCLC stage (B: absence; C, presence); †factors in the univariate analyses with a $P <0.10$ entered multivariate analyses; # All LR patients had assessments of microvascular invasion, whereas it was not available in TACE patients.

LR: liver resection; TACE: transcatheter arterial chemoembolization; HR: hazard ratio; BCLC: Barcelona Clinic Liver Cancer; AFP: alpha fetoprotein; MI: microvascular invasion;
similar to that of TACE- (median, 17.7020 vs. 18.3490, \( P > 0.999 \)), but higher than that of TACE+ (median, 17.7020 vs. 12.8860, \( P < 0.001 \)). Therefore, if LR+ patients are treated by TACE, their survival would be similar to that of the TACE- group and worse than that of the TACE+ group, with severe compromise of OS (Figure 3A).

Second, wavelet-2-V (filter 1.0) was compared between LR- and TACE+, as well as between LR- and TACE-. The results showed that the value of LR- was similar to that of TACE+ (median, 13.1050 vs. 12.8860, \( P > 0.999 \)), but lower than that of TACE- (median, 18.3490, \( P < 0.001 \)). Therefore, if LR- patients are treated by TACE, their survival would be similar to that of TACE+ patients and better than that of TACE- patients, without compromise of OS (Figure 3B).

Third, we compared wavelet-2-H (filter 1.0) between TACE- and LR-, as well as between TACE- and LR+. We observed that TACE- and LR- showed a significant difference (median: 15.3530 vs. 11.8430, \( P < 0.001 \)), whereas TACE- and LR+ did not (median: 15.3530 vs. 15.7260, \( P > 0.999 \)). Therefore, if TACE- patients are treated by LR, their survival would be similar to that of LR+ patients and better than that of LR- patients, and their OS would be considerably improved (Figure 3C).

Lastly, we compared wavelet-2-H (filter 1.0) between TACE+ and LR-, as well as between TACE+ and LR+. We observed that TACE+ and LR+ showed a significant difference (median: 11.5270 vs. 15.7260, \( P < 0.001 \)), whereas TACE+ and LR- did not (median: 11.5270 vs. 11.8430, \( P > 0.999 \)). Therefore, if TACE+ patients

---

**Figure 3: Schematic flow of further validation studies.** Before subgrouping, OS A. and TTP D. showed significant differences between LR and TACE. Upon subgrouping by wavelet-2-H (filter 1.0) in LR and by wavelet-2-V (filter 0) in TACE, LR+ was associated with the best OS, followed by LR- and TACE+; TACE- had the poorest OS B. TTP also showed significant differences, with the TTP of LR+ and LR- being equal to that of TACE+, but better than that of TACE- E. Similar results for OS C. and TTP F. were noted if LR was separated by wavelet-2-H (filter 1.0) and TACE was separated by wavelet-2-V (filter 1.0).
are treated by LR, their OS would be similar to that of LR- patients and worse than that of LR+ patients, with no extension of survival (Figure 3D).

Accordingly, when the TACE group was separated by another prognostic indicator, wavelet-2-V (filter 0), similar results were consistently noted (Figure 2).

**DISCUSSION**

In this study, we took six typical HCC subject image features and textural features into account to determine whether or not they could be used to assist in therapeutic decision-making and optimization. Corona and 29 textural parameters (nine in LR and 20 in TACE) had P-values < 0.10 in the univariate Cox regressions for OS. Sequentially, multivariate Cox regressions and Kaplan-Meier analyses identified four parameters (one in the LR group and three in the TACE group) related to OS.

Filter 1.0 was the best filter, as it showed significant results in both the LR and TACE groups, which was consistent with the findings of published studies [15, 16]. The reason for this result might be that textural features at filter 0 tend to reflect radiologists' impressions of image quality, which could be influenced by image noise. By using filters at larger scales (filter 1.0, 5 pixels), subjective bias might be alleviated, and underlying biologic heterogeneity could be enhanced [14].

In the subgroup comparisons, we noted that TACE would have severely compromised OS in LR+ patients,

![Flowchart for patient inclusion and exclusion.](image-url)

**Figure 4: Flowchart for patient inclusion and exclusion.**
while LR would have considerably improved OS in TACE- patients; thus, LR should be recommended for these patients (Figure 3, blue part). On the other hand, TACE+ patients treated by LR would have no extension of survival, while LR- patients treated by TACE would not have their survival compromised; in these cases, TACE is recommended (Figure 3, red part).

Further validation showed that lower wavelet-2-H (filter 1.0) was simultaneously with lower wavelet-2-V (filter 0 and 1.0) and vice versa, which was consistent with the definition of wavelet-2-H and 2-V, both features were extracted from reconstructed images originating from the same decomposing level (level 2). Thus, single large HCCs (well-preserved liver function, no extrahepatic metastasis) with higher wavelet-2-H (filter 1.0) and wavelet-2-V (filter 0 and 1.0) are considered suitable for LR, whereas those

---

**Table 3: Multivariate Cox regression for overall survival**

| Group | Factors | HR (95% CI) | P   |
|-------|---------|-------------|-----|
| LR    | Filter=0|             |     |
|       | Filter=1.0 |          |     |
| Wavelet-2-H | 0.836 (0.700–0.998) | 0.047 |
| TACE  | Filter=0 |             |     |
| Wavelet-2-V | 1.120 (1.012–1.239) | 0.029 |
| Wavelet-3-D | 3.146 (1.102–8.979) | 0.032 |

Dash indicated no data identified; *6 separate multivariate cox regression were performed, only variables with a statistical significance were listed (no clinical variables or radiologic features were identified after multivariate Cox regression); LR: liver resection; TACE: transcatheter arterial chemoembolization; HR: hazard ratio;

**Table 4: Kaplan-Meier method and Log-rank tests**

| Treatment | Group | OS | TTP |
|-----------|-------|----|-----|
|           |       | mOS # (95%CI) | P   | mTTP# (95%CI) | P   |
| LR        | Wavelet-2-H (filter 1.0) |       |     |
| LR-       | 533 (262–804) | 0.017* | 153 (0–323) | 0.116 |
| LR+       | Less than half died |     | 589 (228–950) |     |
| TACE      | Wavelet-2-V (filter 0) |       |     |
| < 26.4945 | 837 (475–1199) | 0.002 * | 199 (0–420) | 0.166 |
| > 26.4945 | 525 (287–763) | 154 (78–230) |     |
| TACE      | Wavelet-2-V (filter 1.0) |       |     |
| TACE+     | 837 (475–1199) | 0.002 * | 199 (0–420) | 0.166 |
| TACE-     | 525 (287–763) | 154 (78–230) |     |
| TACE      | Wavelet-3-D (filter 1.5) |       |     |
| ≤ 2.4300  | 637 (318–956) | 0.581 | 94 (30–158) | 0.118 |
| > 2.4300  | 548 (278–818) | 260 (0–547) |     |

# Unit: days; *with a statistical difference;
LR-: LR patients with wavelet-2-H (filter 1.0) <13.2890; LR+: LR patients with wavelet-2-H (filter 1.0) >13.2890; TACE-: TACE patients with wavelet-2-V (filter 1.0) < 15.7150; TACE+: TACE patients with wavelet-2-V (filter 1.0) >15.7150; OS: overall survival; TTP: time to progression; LR: liver resection; TACE: transcatheter arterial chemoembolization
with lower values might be recommended for TACE (Figure 3). Additionally, similar conclusions could also be drawn if separated by the receiver operating characteristic curve threshold (Figure S1 & S2).

Although BCLC stage C used to be considered a contradiction for both TACE and LR in HCC, recent studies showed that both TACE and LR could provide survival benefit [26-28]. Nevertheless, patient selection was crucial before LR or TACE. So, we included HCCs in BCLC stage C in our study. Furthermore, in clinical observations, sorafenib alone seldom led to necrosis in intrahepatic/extrahepatic lesions or shrinkage in thrombosis. Given that no more effective treatments are recommended by the BCLC staging system, BCLC stage C HCC patients would have significantly shorter survival times than stage B patients. However, in this study, patients in BCLC C stage only had thrombosis at bifurcations. In this situation, the branches involved could be removed by resection or embolized by TACE. Therefore, intrahepatic lesions and branch vascular invasion could be treated simultaneously. This might be one explanation for why the BCLC did not have prognostic value in this study. Nevertheless, our results should be considered as preliminary, and further study is warranted.

In HCC prognosis, tumor stage and accurate evaluation of the liver-function reserve need to be incorporated [5]. Thus, the presence of cancer-related symptoms, liver function, alpha-fetoprotein, and Child-Pugh score were adjusted for, with no significant differences observed, and subgrouping according to texture analysis proved to be the only factor significantly related to OS. For TTP, subgrouping showed significant differences in the Kaplan-Meier survival curves, but not in the Cox regression. The reason for this observation might be that in the initial screen by Cox regressions, we used survival status (OS) as the event, which probably excluded some parameters related to TTP.

Texture analysis is associated with challenges in image acquisition. In a previous phantom study, texture parameters were demonstrated to be relatively sensitive to tube voltage, but to be independent of the tube current [29]. Additionally, one study showed that hepatic texture features were less sensitive to changes in CT acquisition parameters [30]. Slice thickness is another major determinant of textural parameters [31], with one study revealing that a slice thickness of ≤ 3 mm was optimal for feature grading [32]. Thus, we carefully excluded images outside this criterion in the present study, which might have partly reduced the influence of textural parameter reproducibility in prognostic evaluation.

This retrospective study had some limitations. First, this study included a relatively small sample size. However, in an attempt to control for possible confounding effects, patients with multiple lesions or extrahepatic metastasis were excluded. Second, the retrospective design of this study did not include some potential confounding factors. In particular, the prevalence of comorbidities that might influence liver texture, such as diabetes, alcoholic liver disease, and early cirrhosis was unknown and needs to be assessed in future studies. Further, the possibility of selection bias could not be eliminated. Finally, in this study, all ROIs were manually drawn by the two radiologists rather than by automatic segmentation. However, excellent inter-observer agreement was observed. Future adoption of a more robust algorithm is warranted.

In conclusion, textural variations on baseline CT images might offer more thorough insight for HCC prognosis. Additionally, detailed grouping by wavelet features showed the feasibility of this method in patient stratification. Though further validation is still warranted, texture analysis could potentially be used to inform the LR vs. TACE decision-making strategy.

**MATERIALS AND METHODS**

**Patients**

This study was approved by the Ethics Committee of Guangdong General Hospital. Informed consent was waived due to the retrospective design of the study, and all patient records and information were anonymized and de-identified prior to analysis.

Between September 2009 and December 2014, 130 patients with a single large HCC (> 5 cm) initially treated by LR or TACE were enrolled (Figure 4). The time interval between baseline CT and initial treatment was less than 14 days. For BCLC stage C, only patients with branch vascular invasion were included, whereas those with extrahepatic metastasis and main portal vein thrombosis were excluded due to limited efficacy of LR/TACE for these patients. For all enrolled patients (if still alive by the study end date of March 2015), at least a three-year follow-up was required; patients diagnosed after March 2012 without death were excluded from this requirement.

In this study, we employed the BCLC classification instead of TNM, as the BCLC classification is more informative than TNM regarding survival outcomes and therapeutic strategies [2, 3]. In the BCLC classification, disputes exist on the classification of single HCCs > 5 cm without vascular invasion and extrahepatic metastasis as stage A or B [5, 28]. Herein, we used stage AB, as proposed by a previous study [28]. As a result, single HCCs > 5 cm with well-preserved liver function (Child Pugh A-B cirrhosis, and PST < 1) were classified as stage AB (without vascular invasion) and stage C (with vascular invasion). Patients with PST = 1 but without vascular invasion were still classified as stage AB, which was in accordance with two studies [28, 33].

Anatomical or non-anatomical LR was performed
with a margin > 10 mm. All TACE procedures in this study were performed by Seldinger’s technique, with epirubicin, lobaplatin and lipiodol mixed as the embolic agent.

Follow-up and endpoint

The follow-up interval was 4-8 weeks, and included routine laboratory tests, chest X-ray and abdominal CT. Additional CT or magnetic resonance imaging was routinely performed if extrahepatic metastasis was suspected.

The primary endpoint was OS, and the secondary endpoint was time to progression (TTP). Disease progression for TACE was defined as an increase of at least 20% in the diameter of a viable target lesion according to the modified Response Evaluation Criteria in Solid Tumors. Disease progression for the LR group was defined as intrahepatic or extrahepatic recurrence.

CT examination

All baseline images were derived from our picture archiving and communication system. Portal-phase CT of liver was obtained by the same scanner (LightSpeed VCT 64; GE Medical Systems, Waukesha, WI). After administering iopamidol (370 mg of iodine/mL, Iopamiro; Bracco, Milan, Italy), a non-ionic contrast medium, at 1.5 mL/kg (maximum dose, 100 mL) with a double-tube high-pressure syringe at 3.5 mL/s, hepatic imaging acquisition was performed at fixed time points at the portal venous phase at a 70 sec delay. The scan parameters were as follows: 120 kV; automatic mA, 80-500 mA; noise index: 7; pitch/table speed = 0.984/39.37 mm/rot; rotation time, 0.6 s; field of view, 300-450 mm; matrix, 512 mm. A slice thickness of 1.25 mm was routinely reconstructed with soft kernels.

Inspired by one study [34], typical subjective imaging features were analyzed to explore the potential of the conventional image phenotype on HCC prognosis. Six features, including the shape (noninvasive or invasive), capsule (absence, not integral, or integral), corona (negative or positive), mosaic (negative or positive), node-in-node (negative or positive), and enhanced region relative to the entire tumor (< 25%, 25%-50%, 50%-75%, > 75%) were consensus-classified by two radiologists (Figure S3).

Texture analysis methodology

For each pre-treatment examination, 1.25-mm axial images obtained at the portal venous phase through the largest cross-sectional area of the tumor were selected and transferred to two personal computers for texture analysis. The process of texture analysis comprised three steps:

(1) Image filtration: Laplacian of Gaussian (LoG) spatial band-pass filters were used to reduce the sensitivity to noise. Filter width and sigma (σ) are the two parameters that characterize LoG filter weighting. Three σ values (0, 1.0, and 1.5) and a single filter-width of σ*5 pixels were used (Table S2). Pixels with attenuation of less than -50 HU were removed. The filtration process produced a series of images displaying textual features at different filters.

(2) Wavelet analysis: The use of the wavelet transform for texture analysis was first proposed by Mallat [35]. This transform provides a robust methodology for texture analysis in different scales. Initially, it decomposes each image and receives its texture by using a series of elemental functions called wavelet and scaling, where “s” governs the scaling and “u” the translation, as follows:

\[ \phi_{s,u}(x) = \frac{1}{\sqrt{s}} \phi \left( \frac{x-u}{s} \right) \quad (s \in \mathbb{R}^+ \quad u \in \mathbb{R}) \]

As a result, the Haar wavelet transform decomposes each original image into nine images with different scales, called trends and fluctuations:

\[ W(s,u) = \int f(x) \frac{1}{\sqrt{s}} \phi \left( \frac{x-u}{s} \right) \, dx \]

The former are averaged versions of the original image, and the latter contains the high frequencies. Each image is decomposed into 1, 2, or 3 levels and reconstructed in three directions (diagonal, horizontal, and vertical).

(3) Texture feature extraction: Two radiologists (Readers 1 and 2, with 5 and 4 years of experience in abdominal CT interpretation, respectively) independently performed textural feature extraction and quantification using ImageJ software (National Institutes of Health, Bethesda, MD). For each reader, a user-defined irregular ROI was drawn manually around the largest cross-sectional tumor outline and copied to the nine derived texture feature maps. Subsequently, the values of the texture features were measured and saved for further analysis.

Statistical analyses

The Shapiro-Wilk test was applied to assess normality. Differences in patient demographics and characteristics for those undergoing LR or TACE were tested using independent-sample t-tests, Mann-Whitney U tests and Chi-square tests. Inter-observer agreement on textual features was evaluated using intraclass correlation coefficients (ICCs) [36].

Patient demographics and subjective imaging features were included for adjustment in the analyses. Univariable Cox regression was used as a preliminary screening of candidate variables. Variables of statistical significance in the univariate analysis \((P < 0.10)\) were used as input variables for the subsequent multivariate...
Cox regression models (Forward: LR method). Textural features at each filter were tested in separate models to assess the independent effects of the CT texture of the primary tumor on OS. Thus, six multivariate models were created (one per group per filter; LR and TACE groups, and three filters). Afterwards, the median values of the independent texture parameters were used to separate patients in the LR and TACE groups for subsequent Kaplan-Meier analysis.

To explore the potential role of texture features in deciding between LR and TACE, patients were first divided into two subgroups according to the identified prognostic markers in the LR and TACE groups. Cox regression for all patients was performed to determine whether subgrouping was an independent factor for OS and TTP. Next, one way-ANOVA or Kruskal-Wallis H was used to compare the identified textural parameters among the subgroups. Post hoc multiple comparisons were performed using Bonferroni’s correction or Dunnett’s T3 test.

The thresholds of the identified factors in Cox regression models were also determined using standard receiver operating characteristic curves. Figure S1 & S2 contain detailed discussions regarding this approach.

All statistical analyses were performed with SPSS 20.0 (IBM SPSS Statistics, Armonk, NY). A two-tailed P value of less than 0.05 was considered statistically significant.

ACKNOWLEDGMENTS

All authors have declared no conflicts of interest.

FINANCIAL SUPPORT

We would like to thank Shengli An (Department of Biostatistics, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou) for statistical advice for this manuscript.

CONFLICTS OF INTEREST

All authors have declared no conflicts of interest.

REFERENCES

1. Njei B, Rotman Y, Ditah I and Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015; 61:191-199.
2. Bruix J, Sherman M and Practice Guidelines Committee AAfISoLD. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208-1236.
3. European Association For The Study Of The L, European Organisation For R and Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 2012; 56:908-943.
4. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255.
5. Forner A, Gilabert M, Bruix J and Raoul J. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014; 11:525-535.
6. Maluccio M and Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA. 2012; 62:394-399.
7. Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, Cescon M, Ercolani G, Tuci F, Cillo U and Pinna AD. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology. 2015; 61:905-914.
8. Romagnoli R, Mazzaferrro V and Bruix J. Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. Hepatology. 2015; 62:340-342.
9. Bruix J, Sherman M and American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-1022.
10. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul J and Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Seminars in liver disease. 2012; 32:348-359.
11. Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Duber C, Lang H, Otto G, Worns MA and Galle PR. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver international. 2015; 35:591-600.
12. Parmar C, Leijenaar RT, Grossmann P, Rios Velazquez E, Bussink J, Rietveld D, Rietbergen MM, Haibe-Kains B, Lambin P and Aerts HJ. Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer. Sci Rep. 2015; 5:11044.
13. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A and Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011; 261:165-171.
14. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ and Miles KA. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2013; 266:326-336.
15. Ng F, Ganeshan B, Kozarski R, Miles KA and Goh V. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology. 2013; 266:177-184.
16. Zhang H, Graham CM, Elci O, Griswold ME, Zhang X, Khan MA, Pitman K, Caudell JJ, Hamilton RD, Ganeshan B and Smith AD. Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis
allow independent prediction of overall survival in patients treated with induction chemotherapy. Radiology. 2013; 269:801-809.

17. Yip C, Landau D, Kozarski R, Ganeshan B, Thomas R, Michaelidou A and Goh V. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology. 2014; 270:141-148.

18. Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, Ganeshan B, Miles KA, Cook GJ and Goh V. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights into imaging. 2012; 3:573-589.

19. Lunt SJ, Chaudary N and Hill RP. The tumor microenvironment and metastatic disease. Clinical & experimental metastasis. 2009; 26:19-34.

20. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S and Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. European radiology. 2012; 22:796-802.

21. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chan BK, Matcuk GR, Barry CT, Chang HY and Kuo MD. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007; 25:675-680.

22. Huang YL, Chen JH and Shen WC. Diagnosis of hepatic tumors with texture analysis in nonenhanced computed tomography images. Academic radiology. 2006; 13:713-720.

23. Barry B, Buch K, Soto JA, Jara H, Nakhmani A and Anderson SW. Quantifying liver fibrosis through the application of texture analysis to diffusion weighted imaging. Magnetic resonance imaging. 2014; 32:84-90.

24. Romero-Gomez M, Gomez-Gonzalez E, Madrazo A, Vera-Valencia M, Rodrigo L, Perez-Alvarez R, Perez-Lopez R, Castellano-Megias VM, Nevado-Santos M, Alcon JC, Sola R, Perez-Moreno JM, Navarro JM, Andrade RJ, Salmeron J, Fernandez-Lopez M, et al. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology. 2008; 47:810-816.

25. Simpson AL, Adams LB, Allen PJ, D’Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Leung U, Miga MI, Parada EP, Jarnagin WR and Do RK. Texture analysis of preoperative CT images for prediction of postoperative hepatic insufficiency: a preliminary study. Journal of the American College of Surgeons. 2015; 220:339-346.

26. Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS and Lau WY. Hepatic resection versus transcatheater arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012; 118:4725-4736.

27. Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW and Yoo BC. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver international. 2014; 34:795-801.

28. Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. Journal of hepatology. 2015; 62:617-624.

29. Miles KA, Ganeshan B, Griffiths MR, Young RC and Chatwin CR. Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. Radiology. 2009; 250:444-452.

30. Ganeshan B, Burnand K, Young R, Chatwin C and Miles K. Dynamic contrast-enhanced texture analysis of the liver: initial assessment in colorectal cancer. Investigative radiology. 2011; 46:160-168.

31. Guggenbuhl P, Chappard D, Garreau M, Bansard JY, Chales G and Rolland Y. Reproducibility of CT-based bone texture parameters of cancellous calf bone samples: influence of slice thickness. European journal of radiology. 2008; 67:514-520.

32. Bauer JS, Muller D, Ambekar A, Dobritz M, Matsuura M, Eckstein F, Rummeny EJ and Link TM. Detection of osteoporotic vertebral fractures using multidetector CT. Osteoporosis international. 2006; 17:608-615.

33. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiu YY, Lee FY and Huo TI. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013; 57:112-119.

34. Choi JY, Lee JM and Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014; 273:30-50.

35. Mallat SG. A theory for multiresolution signal decomposition: the wavelet representation. Pattern Analysis and Machine Intelligence, IEEE Transactions on. 1989; 11:674-693.

36. Shrout PE and Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological bulletin. 1979; 86:420-428.